Recent News
Read ArticleDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
Phase 1/2 COMPARE trial of CD19 CAR-T Rx in 6 ACPA+ RA pts w/ severe refractory Dz; after lymphodepletion, given mivocabtagene autoleucel (miv-cel), followed < 52wks. All had CRS, No ICANSs or serious AEs. All had CD19 cell depletion & Decr in AutoAbs. Efficacy: 3/6 had ACR70 & https://t.co/28dWMGWbKB
Dr. John Cush @RheumNow ( View Tweet)
🔍What do long-term treatment data show about reducing flares in GCA?
See the results of continuous JAKi treatment for up to 2 years in this post hoc analysis from SELECT-GCA: https://t.co/yZlC3YIxQH
Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/qEMDlXsBHi
Dr. John Cush @RheumNow ( View Tweet)
“Common sense is the measure of the possible; it is composed of experience and prevision; it is calculation applied to life”
- Henri Frederic Ami
Dr. John Cush @RheumNow ( View Tweet)
FDA Approves Brepocitinib to Treat Dermatomyositis in Adults. Marketed as "Lisraya" it is a once-daily oral tablet that is a JAK/TYK2 inhibitor. Brepocitinibs efficacy was proven in the Ph III VALOR study of 241 DM pts Rx 52-weeks w/ both skin, motor and functional benefits. https://t.co/JXGXJyh0CI
Dr. John Cush @RheumNow ( View Tweet)
Guidelines for Adult-Onset IgA Vasculitis
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology, and pathology published evidence-based guidelines for adult-onset IgAV, which behaves very differently in adults than the usually https://t.co/12T8lJhPFe
Dr. John Cush @RheumNow ( View Tweet)
Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/paUlV4kdwJ
Dr. John Cush @RheumNow ( View Tweet)
CAR-T Reality Check!
The hype is outrunning the evidence, which now lives in a handy dashboard created and presented by Dr. Mike Putman @EBRheum. There are almost as many studies as there are CAR-T treated patients. Few numbers, limited F/U - Yet everyone is gaga about CAR-T. https://t.co/6tLLJDVI8x
Dr. John Cush @RheumNow ( View Tweet)
Glucocorticoids: Use vs.Toxicity
This review article addresses the recognition, prevention and management of GC toxicity in rheumatic patients. Despite guidelines and recommendations that GC be tapered, lowered or discontinued, they continue to be widely used with serious https://t.co/Tf8YkQ9iFB
Dr. John Cush @RheumNow ( View Tweet)
39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower https://t.co/PYuvyaPdxA
Dr. John Cush @RheumNow ( View Tweet)
Per adult-onset IgA vasculitis guidelines, which agent is now preferred for refractory or relapsing disease?
Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/7tMcDkoCKH
Dr. John Cush @RheumNow ( View Tweet)
FDA Approves Brepocitinib to Treat Dermatomyositis
Yesterday the FDA and Priovant annouced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM. Brepocitinibs efficacy was proven in the Ph III VALOR study of 241 DM pts Rx 52-weeks w/ both skin, motor and functional benefits.
Read Article
True or False: A meta-analysis of 61 studies found that exercise showed anti-inflammatory trends, including reductions in CRP, IL-6, and TNF-α, in most chronic diseases.
Test your knowledge in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/7MxkveOuZE
Dr. John Cush @RheumNow ( View Tweet)
JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS)
POTS is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.
https://t.co/dAKlTp4VK3 https://t.co/A2UvgYOQN1
Dr. John Cush @RheumNow ( View Tweet)
The Scleroderma Research Foundation (SRF) will konor John Stamos with the Bob Saget Legacy Award at this year's "Cool Comedy • Hot Cuisine" ceremony that will take place Tuesday, October 13, 2026, at the Beverly Wilshire in Los Angeles. Proceeds will support the SRF https://t.co/VHIpBJrXd4
Dr. John Cush @RheumNow ( View Tweet)
Japanese study of 101 864 children shows fertility treatments (ovulation induction, intrauterine insemination, invitro fertilization) increases the risk of Kawasaki Dz. Incidence rates per 100K PYs - 274 for spont conception vs 391 for assisted conception (adj HR 1.42; https://t.co/Ro0beSXAAq
Dr. John Cush @RheumNow ( View Tweet)
Secukinumab in Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.
Guidelines for Adult-Onset IgA Vasculitis
A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology, and pathology published evidence-based guidelines for adult-onset IgAV, which behaves very differently in adults than the usually https://t.co/mNuL4TG9Ua
Dr. John Cush @RheumNow ( View Tweet)
Age-specific Incidence of Systemic Lupus Erythematosus
Epidemiologic estimates on SLE diagnosis are limited. The CDC National Lupus Registry network of population-based SLE registries has assessed and reported age-specific incidence of SLE by sex, race, and ethnicity. https://t.co/g5A7DMQIyp
Dr. John Cush @RheumNow ( View Tweet)
Phase 1/2 COMPARE trial of CD19 CAR-T Rx in 6 ACPA+ RA pts w/ severe refractory Dz; after lymphodepletion, given mivocabtagene autoleucel (miv-cel), followed < 52wks. All had CRS, No ICANSs or serious AEs. All had CD19 cell depletion & Decr in AutoAbs. Efficacy: 3/6 had ACR70 & https://t.co/qfSdq2g0rk
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
DERM on RheumNow PODCAST (August 2026)
NME: New Molecular Entities (8.28.2026)
Label update: Structural damage progression in active PsA-
Rheum Scholarship (8.21.2026)
Therapeutic Updates
Make Rheum for Rads: Autoimmune ILD Diagnosis, Monitoring, and the Patient Experience
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Drs. Elizabeth Volkmann and Robert Suh explore the roles rheumatologists and radiologists play in diagnosing and monitoring autoimmune ILD and hear from a patient about her experience.
Read Post
A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026.
Read Post
Label update: Structural damage progression in active PsA
Sponsored by Johnson & Johnson Medical Affairs
Listen to Dr. Catherine Bakewell’s review of clinical data from a recent label update.
Read Post
Poster Hall
